Abstract：Objective To investigate the application effect of double long-acting bronchodilator in the stable stage of chronic obstructive pulmonary disease (COPD).Methods A total of 78 COPD stable patients admitted to Suqian Hospital of Traditional Chinese Medicine from January 2019 to March 2021 were selected and divided into observation group and control group by random number table method,with 39 cases in each group.Patients in control group were treated with Tiotropium Bromide Inhalation Powder,and patients in observation group were treated with Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation.Serum levels of tumor necrosis factor α (TNF-α),interleukin (IL)-8,IL-10,C1q tumor necrosis factor associated protein 9 (CTRP-9),soluble late glycation end product receptor (sRAGE),forced expiratory volume in 1 second (FEV1),forced vital capacity (FVC),peak expiratory flow rate (PEF) and the incidence of adverse reactions were compared between two groups.Results There were no significant differences in TNF-α,IL-8 and IL-10 levels between two groups before treatment (P＞0.05).After treatment,the levels of TNF-α,IL-8 in the two groups were lower than those before treatment,and the observation group was lower than that in the control group,the levels of IL-10 in the two groups were higher than those before treatment,and the observation group was higher than that in control group,the differences were statistically significant (P＜0.05).There were no significant differences in FEV1,FVC and PEF between the two groups before treatment (P＞0.05).After treatment,FEV1,FVC and PEF in the two groups were higher than those before treatment,and the observation group was higher than the control group,the differences were statistically significant (P＜0.05).There were no significant differences in serum CTRP-9 and sRAGE between the two groups before treatment (P＞0.05).After treatment,the CTRP-9 of the two groups were lower than those before treatment,and the sRAGE of the observation group was lower than that in the control group,and the sRAGE was higher than that in the control group,the differences were statistically significant (P＜0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05).Conclusion Treatment with dual longacting bronchial dilator Umeclidinium Bromide and Vilanterol Trifenatate Powder for Inhalation can reduce the release of inflammatory factors in stable COPD patients and improve lung function,with high safety.At the same time,it can also reduce the level of serum CTRP-9,improve the level of serum sRAGE and improve the symptoms of disease.
Fiorentino G，Esquinas AM，Annunziata A.Exercise and Chronic Obstructive Pulmonary Disease （COPD）[J].Adv Exp Med Biol，2020，12（28）：355-368.
[9]
Duffy SP，Criner GJ.Chronic Obstructive Pulmonary Disease：Evaluation and Management[J].Med Clin North Am，2019，103（3）：453-461.
[10]
Boof ML，Dingemanse J，Brunke M，et al.Effect of the novel dual orexin receptor antagonist daridorexant on nighttime respiratory function and sleep in patients with moderate chronic obstructive pulmonary disease[J].J Sleep Res，2021，30（4）：e13248.
[11]
Radovanovic D，Santus P，Blasi F，et al.The evidence on tiotropium bromide in asthma：from the rationale to the bedside[J].Multidiscip Respir Med，2017，4（12）：12.
[12]
Rasooli Tehrani A，Gholipour S，Sharifi R，et al.Plasma levels of CTRP-3，CTRP-9 and apelin in women with multiple sclerosis[J].J Neuroimmunol，2019，15（333）：576968.
[13]
Lazarus SC，Krishnan JA，King TS，et al.Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level[J].N Engl J Med，2019，380（21）：2009-2019.
[14]
Ray R，Tombs L，Naya I，et al.Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity：a pooled post hoc analysis of seven clinical trials[J].Pulm Pharmacol Ther，2019，57（20）：101802.
[15]
Kerwin E，ferguson GT，Sanjar S，et al.Dual bronchodilation with indacaterol maleate/glycopyrronium bromide compared with umeclidinium bromide/vilanterol in patients with moderate-to-severe COPD：results from two randomized，controlled，cross-over studies[J].Lung，2017，195（6）：739-747.
[16]
Jerobin J，Ramanjaneya M，Bettahi I，et al.Regulation of circulating CTRP-2/CTRP-9 and GDF-8/GDF-15 by intralipids and insulin in healthy control and polycystic ovary syndrome women following chronic exercise training[J].Lipids Health Dis，2021，20（1）：34.
Du Y，Zhang S，Yu H，et al.Autoantibodies Against β1-Adrenoceptor Exaggerated Ventricular Remodeling by Inhibiting CTRP9 Expression[J].J Am Heart Assoc，2019，8（4）：e010475.
[20]
Prasad K.Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases[J].Mol Cell Biochem，2019，451（1-2）：139-144.
京公网安备 11010502046607号